Kawasaki disease match trial: identifying kids who need treatment
Part of Blood & lymphatic, Heart & circulation, Skin clinical trials.
This trial is testing a way to match children with Kawasaki disease to the best treatment. It looks at specific symptoms and fever duration to see if a child qualifies for the study, which may help doctors give the right treatment faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Fever for at least 3 days (either measured or felt by touch)
- At least one fever measured at home or in the emergency room that is 100.4 degrees Fahrenheit (38.0 Celsius) or higher
- At least one classic sign of Kawasaki disease, like rash, red eyes, changes in mouth or throat, red or swollen hands or feet, or a swollen neck gland (1.5 cm or larger)
- For babies under 6 months old: fever for 7 or more days qualifies even if they do not have classic signs
- Must need a blood draw or IV as part of regular medical care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at children with Kawasaki disease, a condition that causes inflammation in blood vessels. The goal is to learn more about how it affects kids in Europe and North India.
This trial tests whether anakinra is at least as effective as standard treatment for children with Kawasaki disease. It aims to prevent heart complications caused by inflammation in the blood vessels.
This study tests whether an artificial intelligence program can help doctors spot Kawasaki disease earlier by looking at chest X-rays. It compares kids with Kawasaki disease to those with fever from other causes.
This study is for children diagnosed with Kawasaki disease who also develop macrophage activation syndrome (a serious immune complication) within the first month. It aims to better understand and manage this combination.
This study uses heart imaging to better understand Kawasaki disease. It may help doctors assess heart health in affected children and teenagers.
This trial tests adding a new drug, firsekibart, to standard immunoglobulin treatment for children with Kawasaki disease. The goal is to see if the combination is safe and works better than immunoglobulin alone.
Hear when a new Kawasaki Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.